April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Ranibizumab in the real world clinical setting: results from the one year interim analysis of the LUMINOUS study
Author Affiliations & Notes
  • Paul Mitchell
    Ophthalmology, University of Sydney, Sydney, NSW, Australia
  • Footnotes
    Commercial Relationships Paul Mitchell, Abbott (C), Abbott (R), Allergan (C), Allergan (R), Bayer (C), Bayer (R), Novartis (C), Novartis (R)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3062. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Paul Mitchell, ; Ranibizumab in the real world clinical setting: results from the one year interim analysis of the LUMINOUS study. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3062.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To present one year data from the first cohort of wet age related macular degeneration (wAMD) patients recruited in the LUMINOUS study

Methods: LUMINOUS is an ongoing 5-year prospective, multinational, observational study across all approved indications of ranibizumab, designed to evaluate long-term safety, effectiveness, treatment patterns, and health-related quality of life outcomes in patients treated with ranibizumab 0.5 mg in routine clinical practice. The study aims to enroll 30,000 patients from approximately 600 sites in 41 countries worldwide. Of the 2163 patients recruited prior to or on 1st March 2012, 97.6% had wAMD, 1.7% diabetic macular edema and 0.6% retinal vein occlusion. Here, we present the one year safety and effectiveness data for the wAMD cohort (n=2112), of whom 1829 patients had previous ranibizumab treatment (T1), and 275 patients had no prior ranibizumab treatment (T2). 8 patients were previously managed with other ocular treatments (pre-treatment status defined by the primary treated eye)

Results: At baseline, mean age was 79.2 years, 61.7% were female, 93.0% were Caucasian. Mean visual acuity (VA), as early treatment diabetic retinopathy study (ETDRS) letter scores, was higher and central retinal thickness (CRT) was lower for T1 than T2 at baseline (letter scores 60.3 and 52.4, CRT 255.0 and 339.7 µm, respectively). There were no new safety findings reported at the end of the first year, with low rates of ocular (0.4% [T1]; 1.1% [T2]) and non-ocular serious adverse events (8.26% [T1]; 4.73% [T2]). Low rates of endophthalmitis (0.11% [T1]; 0.36% [T2]), cerebrovascular accident (0.22% [T1]; 0.36% [T2]) and myocardial infarction (0.66% [T1]; 0% [T2]) were observed. None of the 37 deaths during the first year of the study (1.7%) were suspected to be related to study drug/injection procedure. At year one, T2 group letter score gain was 4.1 letters, whilst the T1 group maintained their initial higher baseline level VA (-1.1 letter score change). T1 and T2 groups received a mean of 5.2 injections over 7.4 and 7.5 visits, respectively

Conclusions: The outcomes from the first year follow up of LUMINOUS wAMD patients in real-world settings reinforce the well-established efficacy and safety profile of ranibizumab. No new safety findings were observed in this first one year interim analysis of the LUMINOUS study

Keywords: 412 age-related macular degeneration • 505 edema • 669 quality of life  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×